Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lomefloxacin is a fluoroquinolone antibiotic used to treat bacterial infections such as chronic bronchitis and both complicated and uncomplicated urinary tract infections. It is also indicated for the prophylaxis of urinary tract infections in patients undergoing transrectal or transurethral surgical procedures. Lomefloxacin exhibits bactericidal activity against a broad spectrum of gram-negative and gram-positive bacteria, including *Escherichia coli*, *Neisseria gonorrhoeae*, *Streptococcus pneumoniae*, and *Staphylococcus aureus*. Its mechanism of action involves inhibition of the bacterial enzymes DNA gyrase (primarily in gram-negative bacteria) and topoisomerase IV (primarily in gram-positive bacteria), which are essential for DNA replication and transcription. This interference leads to strand breakage, supercoiling abnormalities, inhibition of DNA replication/transcription, and ultimately bacterial cell death[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lomefloxacin.